Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell Acute Lymphoblastic Leukemia

TOP - July 2020, Vol 13, No 4 - AACR Highlights
Wayne Kuznar

A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL).

In a phase 1 dose-escalation study, 8 of the 12 patients with ALL achieved an objective response, and 5 of 8 (63%) patients who received treatment at dose level 2 or 3 achieved a CR. All 5 patients with a CR were negative for minimal residual disease (MRD), said Haneen Shalabi, DO, Assistant Research Physician, Pediatric Oncology Branch, National Cancer Institute, during a presentation at the 2020 American Association for Cancer Research virtual annual meeting. Cytokine release syndrome (CRS) was reversible and neurotoxicity was limited.

Antigen loss escape is a major reason for relapse after CAR T-cell therapy because tumors escape treatment by losing the antigen that the T-cells are targeting. “Our hypothesis was that by simultaneously targeting CD19 and CD22, we could diminish the risk of antigen loss,” said Dr Shalabi.

Of the 15 patients with ALL enrolled in the study, 13 had received treatment, including 4 patients at dose level 1 (3 × 105 transduced CAR T-cells), 4 at dose level 2 (1 × 106 CAR T-cells), and 5 at dose level 3 (3 × 106 CAR T-cells). All of the patients received lymphodepleting therapy with fludarabine and cyclophosphamide before CAR T-cell infusion. The study enrolled a heavily immunotherapy-pretreated population, with 9 (69%) patients receiving previous CD19-targeted CAR T-cell therapy and 5 (38.4%) receiving previous CD22-targeted CAR T-cell therapy. A total of 54% of the patients had previous hematopoietic stem-cell transplantation (HSCT). The median patient age was 19.6 years. A total of 6 (46.2%) patients had extramedullary disease.

Dose-Dependent Effects

The antileukemic effect of CD19/CD22 CAR T-cells was dose dependent. Of the 5 patients who had a CR and attained MRD negativity, 4 were naïve to CAR T-cell therapy.

In all, 2 of the 5 patients with a CR have relapsed with CD19-positive, CD22-positive disease; 1 patient relapsed posttransplant at 265 days after infusion and 1 relapsed at 123 days. Both patients were antigen-positive. A total of 3 patients remain in remission at a median of 7 months postinfusion; 1 patient has an ongoing CR at 7 months without interval therapy and 1 has ongoing CR at 6 weeks postinfusion and is awaiting a second HSCT.

A total of 6 patients had multifocal extramedullary disease in addition to bone marrow disease. Three patients who had clearance of bone marrow disease had persistent extramedullary disease at day 28.

“Discrepancies were seen in marrow response versus extramedullary disease,” said Dr Shalabi. “Discrepant results between marrow and extramedullary disease suggest potentially limited CAR T trafficking to the site of extramedullary disease. Treatment at higher dose levels may be needed to overcome this limitation, and close monitoring and longer follow-up is needed.”

Toxicities were reversible in all patients. A total of 6 (46.1%) patients had CRS, and 2 (15.4%) patients had grade 3 CRS, both at dose level 2. One patient had neurotoxicity at dose level 3.

Limited CAR persistence likely contributed to antigen-positive relapses, said Dr Shalabi. “CAR T-cell expansion was observed in all responders; however, persistence has been limited,” she noted. In the peripheral blood, the median peak percentage of CAR T-cells was 7% (range, 0%-55%) and in the bone marrow at day 28, the median peak was 1.3% (range, 0%-22%). “In the peripheral blood, we can detect CAR T-cells to a median of 45.6 days, with a range of 13 to 87 days,” Dr Shalabi commented.

The investigators plan to explore an additional dose level (1 × 107 CAR T-cells) as well as the intensification of lymphodepletion in patients with previous CAR treatment in an effort to overcome immune-mediated rejection.

The 63% CR rate at the 2 highest dose levels is “quite promising, especially considering that the therapy was very well-tolerated with reversible CRS and neurotoxicity,” commented Yvonne Y. Chen, PhD, Co-Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, University of California, Los Angeles.

Related Items
Personalized Vaccine plus Atezolizumab Shows Promising Clinical Activity in Advanced Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in AACR Highlights
Real-World Analysis Shows Survival Benefit with Adjuvant Immunotherapy in Stage III Melanoma
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in AACR Highlights
COVID-19: Facing the Challenges Ahead
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in AACR Highlights, COVID-19
COVID-19 Increases Overall Risk for Death in Patients with Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in AACR Highlights, COVID-19
Immune Checkpoint Inhibitors Do Not Increase Mortality in Patients with Cancer and COVID-19
Patricia Stewart
TOP - November 2020 Vol 13, No 6 published on November 9, 2020 in AACR Highlights, COVID-19
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Web Exclusives published on August 17, 2020 in AACR Highlights
Early Detection of Cancer Feasible with Blood-Based Tests
Wayne Kuznar
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Value-Based Care
Surgery Is a Viable Treatment Option for Patients with Early-Stage Germ Cell Tumors
Wayne Kuznar
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Survivorship
Universal CAR T-Cells a Promising Off-the-Shelf Therapy for T-Cell Acute Lymphoblastic Leukemia
Wayne Kuznar
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Leukemia, Value-Based Care
Last modified: October 30, 2020